Our passion for conducting clients’ discovery programs is complemented by the pharmaceutical industry experience from both, the management as well as the scientist teams. Each customer is equally important to us and this has been recognized by more than 70% of our business being based on repeated contracts.
We are guided by a truly collaborative mentality, based on transparent processes and open communication. We are providing resources, expertise in a broad range of target classes, know-how, but also a problem-solving attitude and passion for our work.
Axxam is also engaged in alliance-based research towards innovative small molecule therapies for diseases with a high unmet medical need. Axxam’s business terms are flexible, ranging from fee-for-service to risk-sharing deal structures.
Axxam has been accredited by the Italian Government as Innovative SME, under law 24/03/2015 n. 33.
Our capabilities and expertise include:
- Molecular biology (cloning, gene expression analysis, protein expression, genomic engineering)
- Assay development and reagent provision (cellular and biochemical systems)
- Compound management
- Fully automated High-Throughput Screening (various read-outs including also radiometric formats)
- Fully automated High Content Screening and imaging
- Hit characterization & profiling
- Access to the AXXDIV3.0 compound collection (around 275,000 compounds)
- Cardiac safety and liability profiling
These capabilities paired with our discovery mentality have allowed us to successfully execute:
- Hit identification projects
- Hit-to-lead projects
- Lead optimization prgrams